NCT06482853RecruitingEarly phase 1
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- First submitted
- 26 Jun 2024
- Start date
- 23 Jan 2025
- Primary completion date
- Mar 2029
- Lead sponsor
- Milton S. Hershey Medical Center
- Diseases
- Obesity, High blood pressure
- NCT number
- NCT06482853
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 52
- From 23 Jan 2025 to the primary completion date, Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Taking more than two antihypertensive medications
- Women taking hormone replacement therapy within 6 months
- Alcohol or drug abuse
- Treatment with drugs increasing sympathetic activity \[e.g., serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors, stimulants\]
- Treatment with phosphodiesterase-5 inhibitors
- Treatment with anticoagulants (e.g. warfarin)
- Treatment with chronic systemic glucocorticoid therapy (\>7 consecutive days in 1 month)
- Treatment with any investigational drug in the 1-month preceding the study
Other illness
- Secondary causes of hypertension (e.g., pheochromocytoma, primary aldosteronism, aortic coarctation, adrenal disease)
- Decisional impairment
- History of serious cardiovascular disease (e.g. myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g. cerebral hemorrhage, stroke, transient Ischemic attack)
- History or presence of immunological or hematological disorders
Lab values
- Evidence of type I or type II diabetes (fasting glucose \> 126 mg/dL or use of anti-diabetic medications)
- Impaired hepatic function \[aspartate aminotransferase (AST) or alanine transaminase (ALT) levels \>2 times upper limit of normal range\]
- Impaired renal function (serum creatinine \>2.0 mg/dl)
Age
- Age ≤ 17 or ≥ 66 years
Other
- Pregnant or nursing women
- Prisoners
- Current smokers
- Highly trained athletes
- Subjects with \>5% weight change in the past 3 months
- BMI \> 45 kg/m2
- Anemia
- Inability to give, or withdraw, informed consent
Who the study is looking for
- Men and women of all races
- Age 18 to 65 years
- Body mass index (BMI) between 30-45 kg/m2
- Pre-hypertension (defined as two or more seated blood pressure readings \>120/80 mmHg) or hypertension (defined as two or more seated blood pressure readings \>130/80 mmHg or use of antihypertensive medications)
- Capable of giving informed consent
- Fluent in written and spoken English
- Satisfactory history and physical exam
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Penn State Milton S. Hershey Medical Center Coordinator of this site? Confirm its status | Hershey | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.